Eribulin: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Eribulin. Educational only — not medical advice.

Labeled uses

Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. (1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. (1.2 )

Source: FDA labeling via NIH DailyMed (set 64bf3c30…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.